Investors

investor people image

Press Releases

Date Title and Summary Additional Formats
Toggle Summary New stem cell treatment being evaluated for critically ill bone marrow transplant patients
Osiris Launches a Phase II Clinical Trial for Severe Graft vs Host Disease
View HTML
Toggle Summary Osiris Launches the Osteocel Product Line
Bone repair product provides a much needed option for orthopedic surgery
View HTML
Toggle Summary Osiris and JCR Pharmaceuticals Reach Milestone, Expand License Agreement
Companies to expand stem cell technology into a new market opportunity
View HTML
Toggle Summary Osiris Raises $50 Million to Commercialize First Stem Cell Products View HTML
Toggle Summary Osiris Cleared by FDA to Begin Stem Cell Trial for Knee Repair
The announcement marks the third adult stem cell product that Osiris has in human clinical trials.
View HTML
Toggle Summary Osiris Launches the First Trial Using Adult Universal Stem Cells in Cardiac Patients.
Landmark study focuses on promising therapy for the treatment of heart disease.
View HTML
Toggle Summary Osiris First to Announce FDA Fast Track Designation for a Stem Cell Product.
Decision seen as a positive sign for both Osiris and the emerging stem cell industry.
View HTML
Toggle Summary Osiris Therapeutics, Inc. Strengthens Executive Team.
Cary Claiborne named Chief Financial Officer. Harry Carmitchel named Chief Operating Officer.
View HTML
Toggle Summary Stem Cell Therapy Effectively Treats Heart Attacks in Animals
View HTML
Toggle Summary Researchers Turn To Adult Stem Cells View HTML